A Screening Test for HLA-B(∗)15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events

Purpose: HLA-B(∗)15:02 is strongly associated with life-threatening severe skin hypersensitivity reactions in patients treated with carbamazepine (CBZ) and structurally related medications. FDA-approved labeling recommends HLA-B(∗)15:02 screening before CBZ therapy in patients of Asian ancestry. In...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Fang, Hua, Xu, Xiequn, Kaur, Kulvinder, Dedek, Matthew, Zhu, Guang-dan, Riley, Bae J., Espin, Frank G., Del Tredici, Andria L., Moreno, Tanya A.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6443844/
https://ncbi.nlm.nih.gov/pubmed/30971914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00149
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados